ｍRNAテクノロジーを発明したDr. Robert Maloneが安全性に疑問 COVID感染済と１８歳以下の接種に反対表明

 

'The government is not being transparent about the risks': Inventor of MRNA vaccines says people should not be forced to take experimental COVID vaccines because risks aren't known and under 18s and those who’ve had virus shouldn’t take it

• Dr. Robert Malone, inventor of mRNA technology that's used in the COVID vaccine, said young adults and teens shouldn't be forced to get the vaccine 
• He told Fox's Tucker Carlson that there isn't enough risk-benefit analysis data for that age group
• Earlier today, a CDC advisory group said there is a 'likely link' between rare cases of heart inflammation in that age group and the COVID-19 vaccine 

By Christopher Eberhart For Dailymail.Com

Published: 01:22 EDT, 24 June 2021 | Updated: 02:45 EDT, 24 June 2021 

https://www.dailymail.co.uk/news/article-9719891/Inventor-mRNA-vaccines-says-young-adults-teens-not-forced-COVID-vaccine.html

 

RW Malone MD, LLC’s was co-founded and managed by Dr. Malone.

The inventor of mRNA vaccines and one of world’s foremost experts on messenger mRNA therapeutics - having invented the field in 1988, Dr. Malone has extensive research and development experience in the areas of pre-clinical discovery research, clinical trials, vaccines, gene therapy, bio-defense, and immunology. He has over twenty years of management and leadership experience in academia, pharmaceutical and biotechnology industries, as well as in governmental and non-governmental organizations.

Dr. Malone is a specialist in clinical research, medical affairs, regulatory affairs, project management, proposal management (large grants and contracts), vaccines and biodefense. This includes writing, developing, reviewing and managing vaccine, bio-threat and biologics clinical trials and clinical development strategies. He has been involved in developing, designing, and providing oversight of approximately forty phase 1 clinical trials and twenty phase 2 clinical trials, as well as five phase 3 clinical trials. He has served as medical director/medical monitor on approximately forty phase 1 clinical trials, and on twenty phase 2 clinical trials, including those run at vaccine-focused Clinical Research Organizations.

Scientifically trained at UC Davis, UC San Diego, and at the Salk Institute Molecular Biology and Virology laboratories, Dr. Malone is an internationally recognized scientist (virology, immunology, molecular biology) and is known as one of the original inventors of mRNA vaccination and DNA Vaccination. His discoveries in mRNA non viral delivery systems are considered the key to the current COVID-19 vaccine strategies. Dr. Malone holds numerous fundamental domestic and foreign patents in the fields of gene delivery, delivery formulations, and vaccines.

He received his medical training at Northwestern University (MD) and Harvard University (Clinical Research Post Graduate) medical school, and in Pathology at UC Davis.

Dr. Malone has close to 100 peer-reviewed publications and published abstracts and has over 11,477 citations of his peer reviewed publications, as verified by Google Scholar.  His google scholar ranking is “outstanding” for impact factors. He has been an invited speaker at over 50 conferences, has chaired numerous conferences and he has sat on or served as chairperson on numerous NIAID and DoD study sections.

https://www.rwmalonemd.com/

Cationic liposome-mediated RNA transfection

R W Malone, P L Felgner, and I M Verma

See all authors and affiliations

PNAS August 1, 1989 86 (16) 6077-6081; https://doi.org/10.1073/pnas.86.16.6077

Abstract

We have developed an efficient and reproducible method for RNA transfection, using a synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), incorporated into a liposome (lipofectin). Transfection of 10 ng to 5 micrograms of Photinus pyralis luciferase mRNA synthesized in vitro into NIH 3T3 mouse cells yields a linear response of luciferase activity. The procedure can be used to efficiently transfect RNA into human, rat, mouse, Xenopus, and Drosophila cells. Using the RNA/lipofectin transfection procedure, we have analyzed the role of capping and beta-globin 5' and 3' untranslated sequences on the translation efficiency of luciferase RNA synthesized in vitro. Following transfection of NIH 3T3 cells, capped mRNAs with beta-globin untranslated sequences produced at least 1000-fold more luciferase protein than mRNAs lacking these elements.

https://www.pnas.org/content/86/16/6077

、、、（爆ｗｗｗｗｗｗｗｗｗｗｗ